{"id":"https://openalex.org/W3173663900","doi":"https://doi.org/10.2337/db21-751-p","title":"751-P: First-in-Human, Single and Repeated Dose Study of SCO-267, a GPR40 Full Agonist, in Healthy Adults and Subjects with Glucose Intolerance","display_name":"751-P: First-in-Human, Single and Repeated Dose Study of SCO-267, a GPR40 Full Agonist, in Healthy Adults and Subjects with Glucose Intolerance","publication_year":2021,"publication_date":"2021-06-01","ids":{"openalex":"https://openalex.org/W3173663900","doi":"https://doi.org/10.2337/db21-751-p","mag":"3173663900"},"language":"en","primary_location":{"id":"doi:10.2337/db21-751-p","doi":"https://doi.org/10.2337/db21-751-p","is_oa":false,"landing_page_url":"https://doi.org/10.2337/db21-751-p","pdf_url":null,"source":{"id":"https://openalex.org/S129060628","display_name":"Diabetes","issn_l":"0012-1797","issn":["0012-1797","1939-327X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320274","host_organization_name":"American Diabetes Association","host_organization_lineage":["https://openalex.org/P4310320274"],"host_organization_lineage_names":["American Diabetes Association"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5061621850","display_name":"Harunobu Nishizaki","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"HARUNOBU NISHIZAKI","raw_affiliation_strings":["Fujisawa, Japan, Tokyo, Japan, Osaka, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Fujisawa, Japan, Tokyo, Japan, Osaka, Japan","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5020583276","display_name":"Osamu Matsuoka","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"OSAMU MATSUOKA","raw_affiliation_strings":["Fujisawa, Japan, Tokyo, Japan, Osaka, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Fujisawa, Japan, Tokyo, Japan, Osaka, Japan","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058531004","display_name":"Meguru Achira","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"MEGURU ACHIRA","raw_affiliation_strings":["Fujisawa, Japan, Tokyo, Japan, Osaka, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Fujisawa, Japan, Tokyo, Japan, Osaka, Japan","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113155494","display_name":"Tomoya Kagawa","orcid":"https://orcid.org/0009-0005-2439-4969","observed_orcids":["https://orcid.org/0009-0005-2439-4969"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"TOMOYA KAGAWA","raw_affiliation_strings":["Fujisawa, Japan, Tokyo, Japan, Osaka, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Fujisawa, Japan, Tokyo, Japan, Osaka, Japan","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103194228","display_name":"Masanori Watanabe","orcid":"https://orcid.org/0000-0003-2751-2666","observed_orcids":["https://orcid.org/0000-0003-2751-2666"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"MASANORI WATANABE","raw_affiliation_strings":["Fujisawa, Japan, Tokyo, Japan, Osaka, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Fujisawa, Japan, Tokyo, Japan, Osaka, Japan","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5060762563","display_name":"Yusuke Moritoh","orcid":"https://orcid.org/0000-0001-5252-6264","observed_orcids":["https://orcid.org/0000-0001-5252-6264"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"YUSUKE MORITOH","raw_affiliation_strings":["Fujisawa, Japan, Tokyo, Japan, Osaka, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Fujisawa, Japan, Tokyo, Japan, Osaka, Japan","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"70","issue":"Supplement_1","first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.98580002784729,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.98580002784729,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10839","display_name":"Pancreatic function and diabetes","score":0.009200000204145908,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12539","display_name":"Pharmacology and Obesity Treatment","score":0.0006000000284984708,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/gpr40-agonist","display_name":"GPR40 agonist","score":0.9620000123977661},{"id":"https://openalex.org/keywords/impaired-glucose-tolerance","display_name":"impaired glucose tolerance","score":0.8880000114440918},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.7860000133514404},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.7870000004768372},{"id":"https://openalex.org/keywords/islet-hormone-secretion","display_name":"islet hormone secretion","score":0.8420000076293945},{"id":"https://openalex.org/keywords/gut-hormone-secretion","display_name":"gut hormone secretion","score":0.9589999914169312},{"id":"https://openalex.org/keywords/insulin","display_name":"insulin","score":0.8690000176429749},{"id":"https://openalex.org/keywords/glucagon","display_name":"glucagon","score":0.9779999852180481},{"id":"https://openalex.org/keywords/glucagon-like-peptide-1","display_name":"glucagon-like peptide-1","score":0.9810000061988831},{"id":"https://openalex.org/keywords/glucose-dependent-insulinotropic-polypeptide","display_name":"glucose-dependent insulinotropic polypeptide","score":0.9179999828338623},{"id":"https://openalex.org/keywords/peptide-yy","display_name":"peptide YY","score":0.9919999837875366},{"id":"https://openalex.org/keywords/oral-glucose-tolerance-test","display_name":"oral glucose tolerance test","score":0.8240000009536743},{"id":"https://openalex.org/keywords/safety-and-tolerability","display_name":"safety and tolerability","score":0.8360000252723694},{"id":"https://openalex.org/keywords/repeated-dosing","display_name":"repeated dosing","score":0.6890000104904175},{"id":"https://openalex.org/keywords/obesity","display_name":"obesity","score":0.9980000257492065},{"id":"https://openalex.org/keywords/non-alcoholic-steatohepatitis","display_name":"nonalcoholic steatohepatitis","score":0.9990000128746033}],"concepts":[{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.7426422834396362},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7273998260498047},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.7073491811752319},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.7010235786437988},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.6690462231636047},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.6255886554718018},{"id":"https://openalex.org/C2778563252","wikidata":"https://www.wikidata.org/wiki/Q170617","display_name":"Glucagon","level":3,"score":0.5948292016983032},{"id":"https://openalex.org/C32670627","wikidata":"https://www.wikidata.org/wiki/Q18026423","display_name":"Free fatty acid receptor 1","level":4,"score":0.5935717821121216},{"id":"https://openalex.org/C2778938600","wikidata":"https://www.wikidata.org/wiki/Q389934","display_name":"Agonist","level":3,"score":0.5009028911590576},{"id":"https://openalex.org/C2776398474","wikidata":"https://www.wikidata.org/wiki/Q424611","display_name":"Glucagon-like peptide-1","level":4,"score":0.4374805986881256},{"id":"https://openalex.org/C2779306644","wikidata":"https://www.wikidata.org/wiki/Q2002370","display_name":"Insulin","level":2,"score":0.4331378638744354},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.42160043120384216},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.417263388633728},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.3292528986930847},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.20085033774375916},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.18786302208900452},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.2337/db21-751-p","doi":"https://doi.org/10.2337/db21-751-p","is_oa":false,"landing_page_url":"https://doi.org/10.2337/db21-751-p","pdf_url":null,"source":{"id":"https://openalex.org/S129060628","display_name":"Diabetes","issn_l":"0012-1797","issn":["0012-1797","1939-327X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320274","host_organization_name":"American Diabetes Association","host_organization_lineage":["https://openalex.org/P4310320274"],"host_organization_lineage_names":["American Diabetes Association"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/randomized-controlled-trial","display_name":"Randomized Controlled Trial"},{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3186197526","https://openalex.org/W2951097455","https://openalex.org/W7207721592","https://openalex.org/W2948880618","https://openalex.org/W3128945603","https://openalex.org/W1988684782","https://openalex.org/W3084275805","https://openalex.org/W2062958205","https://openalex.org/W3173298221","https://openalex.org/W2809460387"],"abstract_inverted_index":{"The":[0,98,120],"clinical":[1,28,118],"potential":[2,111],"of":[3,59,71,123,142,175,213,258],"SCO-267,":[4],"an":[5,194],"orally":[6],"available":[7],"allosteric":[8],"full":[9,33],"agonist":[10],"against":[11],"GPR40":[12,32],"that":[13,159],"regulates":[14],"islet":[15,241],"and":[16,49,54,63,67,76,88,105,129,132,135,170,185,189,208,218,230,242,246,263],"gut":[17,243],"hormone":[18,244],"secretion,":[19],"is":[20,161],"largely":[21],"unknown.":[22],"Here,":[23],"we":[24],"present":[25],"the":[26,31,110,255],"first":[27],"study":[29,42],"using":[30],"agonist.":[34],"A":[35],"randomized,":[36],"single-center,":[37],"double-blind,":[38],"placebo-controlled,":[39],"phase":[40],"1":[41],"was":[43,85,125,153,226],"conducted":[44],"to":[45,95],"investigate":[46],"safety,":[47],"tolerability,":[48],"pharmacokinetics":[50],"as":[51,56],"primary":[52],"endpoints":[53,58],"pharmacodynamics":[55],"secondary":[57],"single":[60,167],"(5-320":[61],"mg)":[62,172,210],"repeated":[64,150,205],"doses":[65,93],"(80":[66,207],"160":[68,209],"mg,":[69],"Q.D.)":[70],"SCO-267":[72,84,100,124,143,152,166,204,225,238,259],"in":[73,116,144,156,199,220,250],"healthy":[74,133,145,221],"adults":[75,146],"subjects":[77,134,200],"with":[78,137,149,201],"glucose":[79,138,191,196,202,248],"intolerance":[80,192],"(HbA1c":[81],"range":[82],"6.6-8.8%).":[83],"generally":[86,103],"safe":[87],"well":[89,228],"tolerated":[90],"at":[91],"all":[92],"up":[94],"4":[96],"days.":[97],"plasma":[99],"concentration":[101],"increased":[102],"dose-dependently":[104],"its":[106],"pharmacokinetic":[107,121,231],"profiles":[108,122,141,232],"suggests":[109],"for":[112,260],"once-daily":[113,235],"oral":[114,195],"dosing":[115,236],"a":[117,234],"setting.":[119],"similar":[126],"between":[127],"Japanese":[128],"Caucasian":[130],"subjects,":[131],"those":[136],"intolerance.":[139,203],"Pharmacokinetic":[140],"were":[147],"unaltered":[148],"doses.":[151],"hardly":[154],"detected":[155],"urine,":[157],"suggesting":[158],"it":[160],"eliminated":[162],"by":[163],"non-renal":[164],"mechanisms.":[165],"dose":[168,206],"(40":[169],"80":[171],"stimulated":[173,211,240],"secretion":[174,212,245],"insulin,":[176,214],"glucagon,":[177,215],"glucagon-like":[178],"peptide-1":[179],"(GLP-1),":[180],"glucose-dependent":[181],"insulinotropic":[182],"polypeptide":[183],"(GIP),":[184],"peptide":[186],"YY":[187],"(PYY),":[188],"normalized":[190,247],"during":[193],"tolerance":[197,249],"test":[198],"GLP-1,":[216],"GIP,":[217],"PYY":[219],"adults.":[222],"In":[223],"conclusion,":[224],"safe,":[227],"tolerated,":[229],"support":[233,254],"regimen.":[237],"further":[239,256],"humans.":[251],"These":[252],"findings":[253],"development":[257],"diabetes,":[261],"obesity,":[262],"nonalcoholic":[264],"steatohepatitis.":[265],"Disclosure":[266],"H.":[267],"Nishizaki:":[268],"Employee;":[269,279,287,294,301],"Self;":[270,280,288,295,302],"Scohia":[271,289,296,303],"Pharma":[272,290,297,304],"Inc.":[273,291,298,305],"O.":[274],"Matsuoka:":[275],"None.":[276],"M.":[277,292],"Achira:":[278],"PRA":[281],"Health":[282],"Sciences":[283],"KK.":[284],"T.":[285],"Kagawa:":[286],"Watanabe:":[293],"Y.":[299],"Moritoh:":[300]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2021-07-05T00:00:00"}